Retatrutide
Key Takeaways: Retatrutide
Retatrutide is a GLP-1 peptide primarily researched for:
- Potent weight loss (Triple Agonist)
- Blood sugar regulation
- Liver fat reduction
Research Profile
Retatrutide (LY3437943) is an experimental triple hormone receptor agonist (GLP-1, GIP, and Glucagon) developed by Eli Lilly. It is arguably the most potent weight-loss peptide currently in clinical trials.
Mechanism
By targeting three separate metabolic pathways simultaneously, Retatrutide offers a “triple threat” against obesity. The addition of the glucagon receptor agonism increases energy expenditure and helps specifically target liver fat, which distinguishes it from dual agonists like Tirzepatide.
Research Findings
In Phase 2 trials, Retatrutide demonstrated unprecedented weight loss results, with participants at the highest dose losing an average of 24.2% of their body weight over 48 weeks.
Clinical Data & Studies
Key Benefits
- Potent weight loss (Triple Agonist)
- Blood sugar regulation
- Liver fat reduction
- Improved metabolic health
Potential Side Effects
- Nausea
- Gastrointestinal discomfort
- Increased heart rate (transient)
Stability Profile
Stable for ~30 days (95%+)
Significant degradation (up to 40% loss in 30 days)